In MM patients, acid sphingomyelinase (ASM) is significantly up-regulated, which can lead to the increase of ceramide and the decrease of sphingomyelin to cause phospholipid metabolism disorders. This evidence concerns the gene SMPD1 and Miyoshi myopathy.